Ximelagatran for prevention and treatment of venous thromboembolism
Record ID 32004000641
To summarize the available information on the use of ximelagatran (Trade Name Exanta, manufactured by AstraZeneca)in the prevention of venous thromboembolism after major orthopedic surgery. Ximelagatran is the first oral agent in a new class of anticoagulants called 'direct thrombin inhibitors'.
Most of the available evidence regarding venous thromboembolism (VTE) is from studies focusing on its prevention after major orthopedic surgery. Ximelagatran's efficacy is comparable to that of warfarin and low-molecular-weight heparin in this setting. The rates of bleeding complications for this drug and its comparators were not statistically different. The elevation of liver enzymes was observed in longer term trials. Given its simplicity of use, ximelagatran may replace, at least partly, the anticoagulants used in the management of VTE. It use beyond VTE prevention and treatment may be anticipated, given that it has been evaluated in stroke prevention and cardiac trials.
English language abstract:
An English language summary is available
- Venous Thrombosis
Canadian Coordinating Office for Health Technology Assessment
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)